share_log

Reported Earlier, Zai Lab Expands Oncology Pipeline With MediLink Collaboration For Novel LRRC15 ADC ZL-6201

Benzinga ·  14:06

Through this collaboration, Zai Lab further expands its global oncology pipeline with another potential first-in-class ADC targeting multiple solid tumors and addressing significant unmet medical needs. ZL-6201 has demonstrated encouraging preclinical data with an IND expected to be filed in 2025.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment